New hope for Hard-to-Treat breast cancer: Two-Drug cocktail shows promise

NCT ID NCT06963905

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times

Summary

This study is for people with metastatic triple-negative breast cancer that has not responded to one prior treatment. It tests two combinations of drugs: one with sacituzumab govitecan and nivolumab, and another that adds a third drug, relatlimab. The goal is to see which combination is safer and works better at shrinking tumors. About 60 adults will take part, and treatment continues as long as it helps and side effects are manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CANCER